WokVel
Research

These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

Please note that the physiological activity of the ingredient(s) described herein is supported by the referenced clinical trial reports. Marketers of finished products containing the ingredient(s) described herein are responsible for determining whether claims made for such products are lawful and in compliance with the laws of the country in which they will market the products.

WokVel
Research

WokVel
Research

  • Filter Research By Type:

  • Filter Research By Dosage:

Pharmacokinetics of solid lipid Boswellia serrata particles [WokVel® SLP] in healthy subjects.

Kulkarni PD et al.
Drug Metabol Personal Ther. 05 Apr 2021. 0(0). doi: 10.1515/dmdi-2020-0176
The anti-inflammatory activity of Boswellia serrata extracts (BSE) is well known. BSE comprises boswellic acids (BA) such as 3-O-acetyl-11-keto-beta-boswellic acid (AKBA) and 11-keto-boswellic acid (KBA) as major constituents. One of the limitations of BAs is their poor oral bioavailability. The aim of the study was to prepare solid lipid particles of Boswellia serrata extract (SLBSP) to enhance the bioavailability of BAs.

Double-blind trial of solid lipid Boswellia serrata particles (SLBSP) [WokVel® SLP] vs. standardized Boswellia serrata gum extract (BSE) [WokVel®] for OA of knee.

Kulkarni PD et al.
Drug Metabol Personal Ther. 08 Jun 2020. 35(2). doi: 10.1515/dmpt-2020-0104
The present study was planned to investigate the efficacy of SLBSP vs. standardized BSE for symptomatic knee osteoarthritis (OA) treatment. Methods It was a prospective, randomized, double-blind, double-dummy, placebo-controlled, and single-centre clinical trial for symptomatic osteoarthritis of knee.

Comparison of the metabolic stability of solid lipid Boswellia serrata particles [WokVel® SLP] versus plain Boswellia serrata extract [WokVel®] in human hepatocytes (HHL-17).

Gota P et al.
Int J Pharm Chem Biol Sci. 2016. 6(1): 22-27.
In an in vitro study in human hepatocytes HHL-17, WokVel® SLP™ (Solid Lipid Particle) exhibited lesser accumulation of KBA in hepatocytes and low metabolic clearance. With reported extremely low hepatic clearance of AKBA and conferred metabolic stability of KBA in this study, WokVel® SLP™ may have enhanced oral bioavailability of KBA and AKBA compared to WokVel.

Efficacy of solid lipid Boswellia serrata particles (SLBSP) in OA of knee.

Gota P et al.
J Pharm Sci Tech Mgmt. 2015 Jul. 1(2): 70-76.
Patients with osteoarthritis were treated with solid lipid Boswellia serrata particles (SLBSP – WokVel® SLP) capusles for two months. There was significant improvement in pain and function scores of the WOMAC and VAS indices, and the need for rescue analgesics was markedly decreased by 67% during the first month and 76% during the second, compared to baseline.

Prospects of boswellic acids as potential pharmaceutics.

Du Z et al.
Planta Med. 2015. 81(04): 259-271. doi: 10.1055/s-0034-1396313
A comprehensive review on boswellic acids and their potential for clinical applications; bioavailability, different derivatives, and bioavailability enhancement is discussed.

Effect of Boswellia serrata extract [WokVel®] on degenerative OA in in-vitro and in-vivo models.

Nam DE et al.
J Korean Soc Food Sci Nutr. 2014 Apr 2. 43(5). doi: 10.3746/jkfn.2014.43.5.페이지
WokVel® Extract mediated articular cartilage degeneration by preventing extracellular matrix degradation and chondrocyte injury. It significantly reduced and normalized the production of pro-inflammatory biomarkers and also significantly reduced 5-LOX activity and production of PEG2. Researchers indicated that, “one can consider that [WokVel®] extract may be a potential therapeutic treatment for degenerative [OA].”

Frankincense Systematic review.

E. Ernst
BMJ. 2008 Dec 18. 337: a2813. Review. doi: 10.1136/bmj.a2813
Summary and review of various clinical trials on Boswellia serrata with mentions of WokVel® clinicals included.

Open, randomized, controlled clinical trial of Boswellia serrata extract [WokVel®] as compared to valdecoxib in OA of knee.

Sontakke S et al.
Indian J Pharmacol. 2007 Feb. 39(1): 27-29.
Efficacy, safety, and tolerability of WokVel was compared with an NSAID in 66 patients for six months. WokVel exhibited a slower onset; however, persisted even after discontinued supplementation; whereas, the action of the NSAID became evident faster but quickly dissipated after stopping treatment.

Pharmacokinetic study of 11-keto β-boswellic acid.

Sharma S et al.
Phytomedicine. 2004 Feb. 11: 255-260.
A single 333 mg dose of WokVel® was found to lead to plasma concentrations of 11-keto-boswellic acid (KBA) shown to address the pro-inflammatory cytokine 5-lipoxygenase. WokVel® was safe and well tolerated.

Efficacy and tolerability of Boswellia serrata extract [WokVel®] in treatment of OA of knee – A randomized double blind placebo controlled trial.

Kimmatkar N et al.
Phytomedicine. 2003. 10: 3-7.
In this study, 30 subjects were administered either WokVel® or placebo for eight weeks. After a washout period following the first intervention, the groups were crossed to receive the opposite treatment for eight weeks. All subjects that received WokVel® reported decreased knee pain, increased knee flexion, and increased walking distance. The observed differences between WokVel and placebo were reported as statistically significant and clinically relevant.
  • Filter Research By Type:

  • Filter Research By Dosage:

Pharmacokinetics of solid lipid Boswellia serrata particles [WokVel® SLP] in healthy subjects.

Kulkarni PD et al.
Drug Metabol Personal Ther. 05 Apr 2021. 0(0). doi: 10.1515/dmdi-2020-0176
The anti-inflammatory activity of Boswellia serrata extracts (BSE) is well known. BSE comprises boswellic acids (BA) such as 3-O-acetyl-11-keto-beta-boswellic acid (AKBA) and 11-keto-boswellic acid (KBA) as major constituents. One of the limitations of BAs is their poor oral bioavailability. The aim of the study was to prepare solid lipid particles of Boswellia serrata extract (SLBSP) to enhance the bioavailability of BAs.

Double-blind trial of solid lipid Boswellia serrata particles (SLBSP) [WokVel® SLP] vs. standardized Boswellia serrata gum extract (BSE) [WokVel®] for OA of knee.

Kulkarni PD et al.
Drug Metabol Personal Ther. 08 Jun 2020. 35(2). doi: 10.1515/dmpt-2020-0104
The present study was planned to investigate the efficacy of SLBSP vs. standardized BSE for symptomatic knee osteoarthritis (OA) treatment. Methods It was a prospective, randomized, double-blind, double-dummy, placebo-controlled, and single-centre clinical trial for symptomatic osteoarthritis of knee.

Comparison of the metabolic stability of solid lipid Boswellia serrata particles [WokVel® SLP] versus plain Boswellia serrata extract [WokVel®] in human hepatocytes (HHL-17).

Gota P et al.
Int J Pharm Chem Biol Sci. 2016. 6(1): 22-27.
In an in vitro study in human hepatocytes HHL-17, WokVel® SLP™ (Solid Lipid Particle) exhibited lesser accumulation of KBA in hepatocytes and low metabolic clearance. With reported extremely low hepatic clearance of AKBA and conferred metabolic stability of KBA in this study, WokVel® SLP™ may have enhanced oral bioavailability of KBA and AKBA compared to WokVel.

Efficacy of solid lipid Boswellia serrata particles (SLBSP) in OA of knee.

Gota P et al.
J Pharm Sci Tech Mgmt. 2015 Jul. 1(2): 70-76.
Patients with osteoarthritis were treated with solid lipid Boswellia serrata particles (SLBSP – WokVel® SLP) capusles for two months. There was significant improvement in pain and function scores of the WOMAC and VAS indices, and the need for rescue analgesics was markedly decreased by 67% during the first month and 76% during the second, compared to baseline.

Prospects of boswellic acids as potential pharmaceutics.

Du Z et al.
Planta Med. 2015. 81(04): 259-271. doi: 10.1055/s-0034-1396313
A comprehensive review on boswellic acids and their potential for clinical applications; bioavailability, different derivatives, and bioavailability enhancement is discussed.

Effect of Boswellia serrata extract [WokVel®] on degenerative OA in in-vitro and in-vivo models.

Nam DE et al.
J Korean Soc Food Sci Nutr. 2014 Apr 2. 43(5). doi: 10.3746/jkfn.2014.43.5.페이지
WokVel® Extract mediated articular cartilage degeneration by preventing extracellular matrix degradation and chondrocyte injury. It significantly reduced and normalized the production of pro-inflammatory biomarkers and also significantly reduced 5-LOX activity and production of PEG2. Researchers indicated that, “one can consider that [WokVel®] extract may be a potential therapeutic treatment for degenerative [OA].”

Frankincense Systematic review.

E. Ernst
BMJ. 2008 Dec 18. 337: a2813. Review. doi: 10.1136/bmj.a2813
Summary and review of various clinical trials on Boswellia serrata with mentions of WokVel® clinicals included.

Open, randomized, controlled clinical trial of Boswellia serrata extract [WokVel®] as compared to valdecoxib in OA of knee.

Sontakke S et al.
Indian J Pharmacol. 2007 Feb. 39(1): 27-29.
Efficacy, safety, and tolerability of WokVel was compared with an NSAID in 66 patients for six months. WokVel exhibited a slower onset; however, persisted even after discontinued supplementation; whereas, the action of the NSAID became evident faster but quickly dissipated after stopping treatment.

Pharmacokinetic study of 11-keto β-boswellic acid.

Sharma S et al.
Phytomedicine. 2004 Feb. 11: 255-260.
A single 333 mg dose of WokVel® was found to lead to plasma concentrations of 11-keto-boswellic acid (KBA) shown to address the pro-inflammatory cytokine 5-lipoxygenase. WokVel® was safe and well tolerated.

Efficacy and tolerability of Boswellia serrata extract [WokVel®] in treatment of OA of knee – A randomized double blind placebo controlled trial.

Kimmatkar N et al.
Phytomedicine. 2003. 10: 3-7.
In this study, 30 subjects were administered either WokVel® or placebo for eight weeks. After a washout period following the first intervention, the groups were crossed to receive the opposite treatment for eight weeks. All subjects that received WokVel® reported decreased knee pain, increased knee flexion, and increased walking distance. The observed differences between WokVel and placebo were reported as statistically significant and clinically relevant.